VILAS PATIL: Open Payments
NPI 1417044983 · OSWEGO, NY. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,169 in 59 payments from 9 companies in 2025. Trend: 2023 $184 · 2024 $789 · 2025 $1,169
Food & beverage: $1,169
| Company | Payments | Amount |
|---|---|---|
| Neurocrine BioSciences, Inc. | 7 | $217 |
| Alkermes, Inc. | 9 | $166 |
| Teva Pharmaceuticals USA, Inc. | 11 | $146 |
| ABBVIE INC. | 11 | $137 |
| Otsuka America Pharmaceutical, Inc. | 8 | $136 |
| E.R. Squibb & Sons, L.L.C. | 5 | $130 |
| Janssen Pharmaceuticals, Inc | 3 | $99 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 3 | $91 |
| Luye Pharma (USA) Ltd. | 2 | $47 |
Products named: INGREZZA, VRAYLAR, COBENFY, ABILIFY ASIMTUFII, UZEDY, ARISTADA, INVEGA SUSTENNA, CAPLYTA.
Industry payments across NY — which companies pay providers there.
